Can’t Stop Buying This Dividend Juggernaut: ABBV Growth
A long-time investor explains why AbbVie’s mix of rapidly growing immunology drugs and a dependable dividend keeps dr...
Yearly performance of total market index funds provides a broad view of winners and laggards. Use these insights to adjust your exposure today.
28,320 articlesA long-time investor explains why AbbVie’s mix of rapidly growing immunology drugs and a dependable dividend keeps dr...
A blowout quarter sent AeroVironment stock soaring, but the bigger question for investors is whether the drone boom h...
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
In a volatile market, the dividend growth approach that emphasizes rising payouts over big yields is drawing attentio...
A Detroit autoworker’s dream of winning margins meets a global market that’s increasingly dependent on China. This ar...
If you’re hunting for a lifelong holding, the dividend track record of Medtronic is hard to ignore. This piece explai...
Netflix is pivoting toward ads and international growth. This article breaks down the netflix's revenue expected surg...
March brings pockets of opportunity for patient buyers. Explore four durable picks that long-term investors should co...
A groundbreaking 2026 risk study places hail risk homes with exposure on a footing with major hurricane threats, prom...
Analysts are watching every cue as Apple navigates leadership shifts and growth bets. This article breaks down what a...
Inflation data hints that the 2027 cost of living adjustment could be larger for retirees. Yet, higher Medicare premi...
A top-notch example of choosing happiness and financial control, Jennifer Lopez Says Happy single life isn’t about av...